{"title":"神经营养酪氨酸激酶基因融合:肺癌靶向治疗的另一个机会。","authors":"Luis E Raez, Christian Rolfo","doi":"10.2217/lmt-2016-0003","DOIUrl":null,"url":null,"abstract":"2517 (2015). 12 Patel MR, Bauer TM, Liu SV et al. STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J. Clin. Oncol. 33(Suppl.), Abstract 2596 (2015). 13 Burris HA, Brose MS, Shaw AT et al. A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J. Clin. Oncol. 33(Suppl.), Abstract TPS2624 (2015). 14 TRK inhibitor shows early promise. Cancer Discov. doi:10.1158/2159-8290.CDNB2015-165 (2015) (Epub ahead of print).","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"5 1","pages":"1-4"},"PeriodicalIF":0.9000,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2016-0003","citationCount":"1","resultStr":"{\"title\":\"Neurotrophic tyrosine kinase gene fusions: another opportunity for targeting in lung cancer.\",\"authors\":\"Luis E Raez, Christian Rolfo\",\"doi\":\"10.2217/lmt-2016-0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"2517 (2015). 12 Patel MR, Bauer TM, Liu SV et al. STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J. Clin. Oncol. 33(Suppl.), Abstract 2596 (2015). 13 Burris HA, Brose MS, Shaw AT et al. A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J. Clin. Oncol. 33(Suppl.), Abstract TPS2624 (2015). 14 TRK inhibitor shows early promise. Cancer Discov. doi:10.1158/2159-8290.CDNB2015-165 (2015) (Epub ahead of print).\",\"PeriodicalId\":43551,\"journal\":{\"name\":\"Lung Cancer Management\",\"volume\":\"5 1\",\"pages\":\"1-4\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2016-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/lmt-2016-0003\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lung Cancer Management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/lmt-2016-0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2016/3/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2016-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/3/22 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
Neurotrophic tyrosine kinase gene fusions: another opportunity for targeting in lung cancer.
2517 (2015). 12 Patel MR, Bauer TM, Liu SV et al. STARTRK-1: Phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J. Clin. Oncol. 33(Suppl.), Abstract 2596 (2015). 13 Burris HA, Brose MS, Shaw AT et al. A first-in-human study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family. J. Clin. Oncol. 33(Suppl.), Abstract TPS2624 (2015). 14 TRK inhibitor shows early promise. Cancer Discov. doi:10.1158/2159-8290.CDNB2015-165 (2015) (Epub ahead of print).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
